← FDA DRUG APPROVALS

FDA ANDA · ANDA071995

PRAZOSIN HYDROCHLORIDE

Sponsor: TEVA PHARMS

APPLICATION
ANDA071995
TYPE
ANDA
ORIGINAL APPROVAL
1988-09-12
LATEST ACTION
2015-07-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

PRAZOSIN HYDROCHLORIDEPrescription
PRAZOSIN HYDROCHLORIDE EQ 2MG BASE · CAPSULE · ORAL

Approval history

2015-07-21Labeling · Supplement 30 · standardAP
2015-07-21Labeling · Supplement 29 · standardAP
2009-12-24Labeling · Supplement 24AP
2009-12-24Labeling · Supplement 23AP
2002-07-29Manufacturing (CMC) · Supplement 9AP
2002-03-12Manufacturing (CMC) · Supplement 8AP
2001-07-10Manufacturing (CMC) · Supplement 7AP
2000-01-28Manufacturing (CMC) · Supplement 6AP
1998-10-08Manufacturing (CMC) · Supplement 5AP
1995-12-29Manufacturing (CMC) · Supplement 4AP
1995-02-02Manufacturing (CMC) · Supplement 3AP
1992-05-27Manufacturing (CMC) · Supplement 1AP
1992-05-01Labeling · Supplement 2AP
1988-09-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →